Recombinant Anti-Granulysin Mab (HOM-19315)
|Recombinant Human Anti-Human Granulysin Monoclonal Antibody
- Product Overview
- Recombinant humanized antibody expressed in CHO binding to human Granulysin.
- ELISA, WB, IHC, FCM, IP, IF. Optimal dilutions/concentrations should be determined by the end user.
- Molecular Weight
- 145.41 kDa
- >95.0% as determined by analysis by RP-HPLC & analysis by SDS-PAGE.
- Store it under sterile conditions at -20 °C upon receiving. Recommend to pack the antibody into smaller quantities for optimal storage.
- Samples are stable for up to twelve months from date of receipt at - 20°C and are stable for six months at 4 °C.
- Antigen Description
- Granulysin is a substance released by cytotoxic T cells (CD8) when they are attached to infected body cells. It functions to create holes in the target cell membrane and destroy it. Granulysin is able to induce apoptosis in target cells and also has antimicrobial action. Granulysin is a cytolytic and proinflammatory molecule first identified by subtractive hybridization during a search for genes expressed by human cytotoxic T lymphocytes 3–5 days after their activation. It is expressed in cytolytic granules with perforin, a pore forming protein, and granzymes that are also involved in cytolysis. Granulysin is broadly antimicrobial, killing microbes that cause, for example, tuberculosis and malaria, and can destroy some tumors. A series of peptides generated from the amino acid sequence of granulysin are potential antibiotics.
- GNLY; granulysin; LAG2; D2S69E; LAG 2; NKG5; T lymphocyte activation gene 519; TLA519; lymphokine LAG-2; lymphocyte-activation gene 2; T-cell activation protein 519; T-lymphocyte activation gene 519; 519; LAG-2;
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.